Tiziana Life Sciences Ltd. announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease. Expanded access IND?s provide a pathway for patients to gain access to investigational drugs, biologics, and medical devices used to diagnose, monitor, or treat patients with serious diseases or conditions for which there are no comparable or satisfactory therapy options available outside of clinical trials.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.81 USD | 0.00% |
|
-3.57% | +44.64% |
28/06 | Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies | MT |
28/06 | Transcript : Tiziana Life Sciences Ltd - Special Call |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+44.64% | 82.23M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+48.94% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Life Sciences Ltd to Dose First Patient with Moderate Alzheimer's Disease with Foralumab